PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
Worse than MDGL's estimated revenue of 479.20M.
-1.93M
Worse than MDGL's estimated ebitda of 0.
-1.38
Better than MDGL's estimated eps of -13.37.
-41.62M
Better than MDGL's estimated net income of -287.29M.
-1.93M
Worse than MDGL's estimated ebit of 0.
358.54M
Worse than MDGL's estimated sg&a expense of 0.
Analyze DCF forecasts for the company and compare them with competitors.
1.03M
Better than MDGL's revenue of 0.00.
-9.97%
Worse than MDGL's revenue growth rate of 0.00%.
-33.41M
Better than MDGL's ebitda of -293.10M.
-3243.20%
Worse than MDGL's ebitda margin of 100.00%.
-34.10M
Better than MDGL's ebit of -293.57M.
-3311.07%
Worse than MDGL's ebit margin of 100.00%.
699.00K
Worse than MDGL's depreciation of 467.00K.
108.91M
Worse than MDGL's total cash of 358.77M.
10573.79%
Better than MDGL's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
10.13M
Better than MDGL's accounts payable of 23.83M.
983.50%
Worse than MDGL's payables as percentage of revenue of 100.00%.
-366.00K
Better than MDGL's capital expenditure of -217.00K.
-35.53%
Better than MDGL's capex as percentage of revenue of 100.00%.
4.99%
Better than MDGL's weighted average cost of capital (wacc) of 5.15%.
5.02%
Worse than MDGL's cost of equity of 5.01%.
4.08%
Better than MDGL's cost of debt of 12.27%.
-0.23
Worse than MDGL's beta of -0.92.
30.07M
Worse than MDGL's diluted shares outstanding of 21.27M.
1.57M
Better than MDGL's total debt of 119.57M.
49.31M
Worse than MDGL's total equity of 6.18B.
50.89M
Worse than MDGL's total capital of 6.30B.
3.09%
Worse than MDGL's debt weighting of 1.90%.
96.91%
Worse than MDGL's equity weighting of 98.10%.
-32.98M
Better than MDGL's ebiat of -297.51M.
-28.05M
Better than MDGL's unlevered free cash flow of -294.81M.
2.00%
Equal to MDGL's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than MDGL's net debt of 19.55M.
71.33M
Worse than MDGL's equity value of 7.30B.
2.37
Worse than MDGL's equity value per share of 343.00.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.